{"Clinical Trial ID": "NCT00528567", "Intervention": ["INTERVENTION 1:", "Bevacizumab and chemotherapy", "\u25cf Randomized participants to receive bevacizumab and chemotherapy", "INTERVENTION 2:", "- Chemotherapy", "\u25cf Randomized participants to receive chemotherapy alone"], "Eligibility": ["Incorporation criteria:", "<= 18 years in adults;", "Invasive primary breast cancer is operational;", "A definitive loco-regional surgery was performed;", "A primary tumor centrally confirmed as triple negative.", "- Exclusion criteria:", "Locally advanced breast cancers;", "Previous history of breast cancer;", "A clinically significant cardiovascular disease."], "Results": ["Performance measures:", "\u2022 Disease-free survival time (IDFS)", "The IDFS was a composite criterion defined as the time of randomization up to the date of the first occurrence of one of the following events: recurrence of ipsilateral invasive breast cancer (same breast); recurrence of ipsilateral invasive breast cancer (same side of the body) in the local area (axilla, regional lymph nodes, chest wall and/or skin); remote recurrence (evidence of breast cancer at any anatomical site); death due to any cause; contralateral invasive breast cancer (opposite body) or second non-breast primary invasive cancer.", "Duration: Conducted event (up to data threshold: 29 February 2012: up to 49 months)", "Results 1:", "Title of the arm/group: Bevacizumab and chemotherapy", "Description of the arm/group: Randomized participants to receive bevacizumab and chemotherapy", "Total number of participants analysed: 1301", "Median (95% confidence interval)", "Unit of measurement: Month NA [1] (NA to NA)", "Results 2:", "Title of the arm/group: Chemotherapy", "Description of the arm/group: Randomized participants to receive chemotherapy alone", "Total number of participants analysed: 1290", "Median (95% confidence interval)", "Unit of measurement: Month NA [1] (NA to NA)"], "Adverse Events": ["Undesirable Events 1:", "Total: 379/1288 (29.43%)", "- Febrile neutropenia 84/1288 (6.52%)", "Neutropenia 69/1288 (5.36%)", "Leucopenia 8/1288 (0.62%)", "Anemia 1/1288 (0.08%)", "Thrombocytopenia 4/1288 (0.31%)", "Pancytopenia 1/1288 (0.08%)", "1/1288 (0.08%)", "Atrial fibrillation 4/1288 (0.31%)", "Congestive heart failure 6/1288 (0.47%)", "Adverse Events 2:", "Total: 250/1271 (19.67%)", "Febrile neutropenia 59/1271 (4.64 %)", "Neutropenia 38/1271 (2.99 %)", "- Leucopenia 1/1271 (0.08%)", "Anemia 3/1271 (0.24%)", "Thrombocytopenia 0/1271 (0.00 %)", "Pancytopenia 1/1271 (0.08%)", "- Febrile spinal cord aplasia 0/1271 (0.00 %)", "Atrial fibrillation 2/1271 (0.16%)", "Congestive heart failure 0/1271 (0.00 %)"]}